Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.
Saved in:
| Title: | Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer. |
|---|---|
| Authors: | Liu W; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.; National Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China., Huo G; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.; National Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China., Chen P; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.; National Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China. |
| Source: | Frontiers in public health [Front Public Health] 2024 Feb 15; Vol. 12, pp. 1213318. Date of Electronic Publication: 2024 Feb 15 (Print Publication: 2024). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet ISSN: 2296-2565 (Electronic) Linking ISSN: 22962565 NLM ISO Abbreviation: Front Public Health Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
